Novartis and BenevolentAI sign AI oncology deal

Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Bayer begins $240m AI drug discovery project with Exscientia

10 January 2020 Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.

Asia

Insilico Medicine signs $200m AI drug discovery deal

10 October 2019 Hong Kong-based Insilico Medicine has agreed an artificial intelligence breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.

Big Pharma

AstraZeneca partners on AI drug discovery collaboration

2 May 2019 AstraZeneca has begun collaborating with UK-headquartered artificial intelligence company BenevolentAI to use AI and machine learning for the discovery and development of new treatments.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Novartis and BenevolentAI sign AI oncology deal

More on this story

Editor's picks

Editor's picks

More features